La cadena de opciones muestra datos clave de las opciones de acciones de Dentsply Sirona a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Dentsply Sirona..

Dentsply Sirona (NASDAQ:XRAY) Bolsa, Cadena de Opciones

Dentsply Sirona

Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (manufactured dental consumables and lab products) and Sirona Dental Systems (manufactured technologically-advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology and equipment through third-party distributors and the remaining portfolio is either sold to labs and offices through the firm's salesforce or directly to consumers (such as Byte clear aligner).

Dentsply Sirona Inc

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 200 points on Thursday.
The Dow traded up 0.03% to 43,743.75 while the NASDAQ rose 1.30% to 19,231.18. The S&amp;P 500 also rose, gaining, 0.63% to 5,966.19.
Check This Out: <a href="https://www.benzinga.com/news/24/11/41801967/top-3-energy-stocks-that-are-ticking-portfolio-bombs">Top 3 Energy Stocks That Are Ticking Portfolio Bombs</a>
Leading and Lagging Sectors Communication services shares surged by 1.7% on Thursday.
In trading on Thursday, financials shares fell by 1.4%.
Top Headline
U.S. initial jobless claims rose by 3,000 from the previous week to 221,000 in the final week of October, in-line with market expectations.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) shares shot up 43% to $241.00 after the company reported better-than-expected quarterly financial results.</li>
<li>Shares of Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) got a boost, surging 26% to $11.58 after the company announced it evaluated the safety and efficacy of its new clinical trial of Brincidofovir in treating Mpox across Africa. PANTHER will conduct a clinical trial under The Leadership of Africa Centres for Disease Control and Prevention.</li>
<li>Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) shares were also up, gaining 34% to $46.72 following third-quarter earnings.</li>
</ul>
Equities Trading DOWN
<ul>
<li>DENTSPLY SIRONA Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) shares dropped 26% to $17.65 after the company lowered its FY24 guidance and Leerink Partners downgraded the stock from Outperform to Market Perform.</li>
<li>Shares of Digital Turbine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPS#NASDAQ">APPS</a>) were down 49% to $1.66 after the company reported worse-than-expected second-quarter financial results.</li>
<li>CommScope Holding Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COMM#NASDAQ">COMM</a>) was down, falling 23% to $5.32 after the company reported worse-than-expected third-quarter financial results.</li>
</ul>
Commodities In commodity news, oil traded up 1.3% to $72.63 while gold traded up 1.1% at $2,705.70.
Silver traded up 1.8% to $31.89 on Thursday, while copper rose 4.3% to $4.4270.
Euro zone
European shares closed mostly higher today. The eurozone's STOXX 600 gained 0.62%, Germany's DAX gained 1.70% and France's CAC 40 rose 0.76%. Spain's IBEX 35 Index rose 0.65%, while London's FTSE 100 fell 0.32%.
The Bank of England cut its Bank Rate by 25bps to 4.75% at its recent meeting. Retail sales in the Eurozone rose 0.5% month-over-month in September versus a revised 1.1% gain in August. The HCOB Eurozone construction PMI climbed to 43.0 in October from 42.1 in the previous month.
The S&amp;P Global France construction PMI climbed to 42.2 in October from 37.9 in the prior month, while German construction PMI declined to 40.2 in October from 41.7 in the previous month.
Asia Pacific Markets
Asian markets closed mixed on Thursday, with Japan's Nikkei 225 falling 0.25%, Hong Kong's Hang Seng Index gaining 2.02%, China's Shanghai Composite Index gaining 2.57% and India's BSE Sensex falling 1.04%.
China&#8217;s trade surplus widened to $95.27 billion in October from $56.13 billion in the year-ago period. Foreign exchange reserves in Singapore increased to SGD 507.6 billion in October from SGD 499.7 billion in the prior month.
Economics
<ul>
<li>U.S. initial jobless claims rose by 3,000 from the previous week to 221,000 in the final week of October, in-line with market expectations.</li>
<li>U.S. nonfarm business sector labor productivity increased by 2.2% in the third quarter compared to a revised 2.1% gain in the prior three-month period.</li>
<li>Unit labor costs in the nonfarm business sector rose an annualized 1.9% during the third quarter compared to a revised 2.4% increase in the earlier period.</li>
<li>U.S. wholesale inventories fell by 0.2% month-over-month to $903.7 billion in September versus the preliminary reading of a 0.1% decline and compared to a 0.2% gain in the prior month.</li>
<li>U.S. natural-gas stocks rose by 69 billion cubic feet to 3.932 trillion cubic feet in the week ended Nov. 1.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41805406/wall-streets-most-accurate-analysts-spotlight-on-3-industrials-stocks-with-over-5-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Industrials Stocks With Over 5% Dividend Yields</a></li>
</ul>

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

APPS

BROS

COMM

XRAY

Crude Oil Rises 1%; US Jobless Claims Increase To 221,000

U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining more than 1% on Thursday.
The Dow traded up 0.01% to 43,731.14 while the NASDAQ rose 1.19% to 19,208.62. The S&amp;P 500 also rose, gaining, 0.55% to 5,961.80.
Check This Out: <a href="https://www.benzinga.com/news/24/11/41801967/top-3-energy-stocks-that-are-ticking-portfolio-bombs">Top 3 Energy Stocks That Are Ticking Portfolio Bombs</a>
Leading and Lagging Sectors Consumer discretionary shares surged by 1.5% on Thursday.
In trading on Thursday, financials shares fell by 1.3%.
Top Headline
Halliburton Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) reported worse-than-expected third-quarter EPS and sales.
HAL reported a third-quarter revenue decline of 1.8% year-over-year to $5.697 billion, missing the consensus of $5.828 billion. Adjusted EPS was 73 cents, down from 79 cents a year ago and below the consensus of 75 cents.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) shares shot up 43% to $241.02 after the company reported better-than-expected quarterly financial results.</li>
<li>Shares of Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) got a boost, surging 32% to $12.13 after the company announced it evaluated the safety and efficacy of its new clinical trial of Brincidofovir in treating Mpox across Africa. PANTHER will conduct a clinical trial under The Leadership of Africa Centres for Disease Control and Prevention.</li>
<li>Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) shares were also up, gaining 36% to $47.35 following third-quarter earnings.</li>
</ul>
Equities Trading DOWN
<ul>
<li>DENTSPLY SIRONA Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) shares dropped 25% to $17.98 after the company lowered its FY24 guidance and Leerink Partners downgraded the stock from Outperform to Market Perform.</li>
<li>Shares of Digital Turbine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPS#NASDAQ">APPS</a>) were down 45% to $1.7694 after the company reported worse-than-expected second-quarter financial results.</li>
<li>CommScope Holding Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COMM#NASDAQ">COMM</a>) was down, falling 24% to $5.30 after the company reported worse-than-expected third-quarter financial results.</li>
</ul>
Commodities In commodity news, oil traded down 0.3% to $71.46 while gold traded up 1.1% at $2,705.10.
Silver traded up 1.9% to $31.930 on Thursday, while copper rose 4.1% to $4.4185.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.94%, Germany's DAX gained 2.07% and France's CAC 40 rose 1.07%. Spain's IBEX 35 Index rose 1.01%, while London's FTSE 100 rose 0.04%.
The Bank of England cut its Bank Rate by 25bps to 4.75% at its recent meeting. Retail sales in the Eurozone rose 0.5% month-over-month in September versus a revised 1.1% gain in August. The HCOB Eurozone construction PMI climbed to 43.0 in October from 42.1 in the previous month.
The S&amp;P Global France construction PMI climbed to 42.2 in October from 37.9 in the prior month, while German construction PMI declined to 40.2 in October from 41.7 in the previous month.
Asia Pacific Markets
Asian markets closed mixed on Thursday, with Japan's Nikkei 225 falling 0.25%, Hong Kong's Hang Seng Index gaining 2.02%, China's Shanghai Composite Index gaining 2.57% and India's BSE Sensex falling 1.04%.
China&#8217;s trade surplus widened to $95.27 billion in October from $56.13 billion in the year-ago period. Foreign exchange reserves in Singapore increased to SGD 507.6 billion in October from SGD 499.7 billion in the prior month.
Economics
<ul>
<li>U.S. initial jobless claims rose by 3,000 from the previous week to 221,000 in the final week of October, in-line with market expectations.</li>
<li>U.S. nonfarm business sector labor productivity increased by 2.2% in the third quarter compared to a revised 2.1% gain in the prior three-month period.</li>
<li>Unit labor costs in the nonfarm business sector rose an annualized 1.9% during the third quarter compared to a revised 2.4% increase in the earlier period.</li>
<li>U.S. wholesale inventories fell by 0.2% month-over-month to $903.7 billion in September versus the preliminary reading of a 0.1% decline and compared to a 0.2% gain in the prior month.</li>
<li>U.S. natural-gas stocks rose by 69 billion cubic feet to 3.932 trillion cubic feet in the week ended Nov. 1.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41805406/wall-streets-most-accurate-analysts-spotlight-on-3-industrials-stocks-with-over-5-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Industrials Stocks With Over 5% Dividend Yields</a></li>
</ul>

Gold Gains 1%; Halliburton Posts Weak Q3 Results

<h3>Gainers</h3>
<ul>
<li>Celularity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) shares moved upwards by 36.8% to $1.98 during Thursday's regular session. The market value of their outstanding shares is at $43.6 million. As per the news, the Q2 earnings report came out today. </li>
<li>Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) shares moved upwards by 31.25% to $0.95. The market value of their outstanding shares is at $109.4 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares increased by 30.76% to $12.03. The market value of their outstanding shares is at $630.3 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock increased by 29.17% to $0.71. The market value of their outstanding shares is at $10.6 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock rose 23.03% to $0.08. The market value of their outstanding shares is at $4.0 million. </li>
<li>Myomo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MYO#AMEX">MYO</a>) shares rose 19.61% to $5.0. The company's market cap stands at $151.1 million. As per the press release, Q3 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) shares fell 28.7% to $0.92 during Thursday's regular session. The company's market cap stands at $40.4 million. </li>
<li>Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) shares fell 24.69% to $18.06. The company's market cap stands at $3.6 billion. As per the news, the Q3 earnings report came out today. </li>
<li>Personalis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) shares declined by 19.54% to $4.49. The market value of their outstanding shares is at $296.0 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Axogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXGN#NASDAQ">AXGN</a>) shares decreased by 17.75% to $12.61. The company's market cap stands at $552.6 million. The company's, Q3 earnings came out today. </li>
<li>Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) shares fell 17.56% to $2.33. The market value of their outstanding shares is at $101.3 million. As per the press release, Q3 earnings came out today. </li>
<li>Clover Health Investments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) shares decreased by 16.41% to $3.64. The market value of their outstanding shares is at $1.8 billion. As per the press release, Q3 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AXGN

CELU

CHRS

CLOV

ENSC

HBIO

PSNL

12 Health Care Stocks Moving In Thursday's Intraday Session

Dentsply Sirona Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) shares are <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">trading lower on Thursday.</a>
The company reported third-quarter adjusted earnings per share of 50 cents, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41800400/dentsply-sirona-reports-third-quarter-2024-results" rel="noreferrer noopener">beating the street view of 47 cents</a>. Quarterly sales of $951 million (increased 0.5%) outpaced the analyst consensus estimate of $939.10 million.
The company recorded a $495 million non-cash goodwill impairment charge in the Orthodontic and Implant Solutions segment. This was due to ongoing economic challenges, legislative changes affecting Byte, weaker demand, increased competition in implants, and lower expected lab material volumes.
Segment wise, Connected Technology Solutions fell 2.3%, Essential Dental Solutions gained 6.6%, Orthodontic and Implant Solutions slumped 4.6%, while Wellspect Healthcare fell 0.4%.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41811560/steve-madden-q3-earnings-top-estimates-as-revenue-jumps-13-lifts-2024-outlook" rel="noreferrer noopener">Steve Madden Q3 Earnings Top Estimates As Revenue Jumps 13%, Lifts 2024 Outlook</a>
Quarterly adjusted EBITDA fell 1.8% to $170 million. Adjusted EBITDA Margin contracted to 17.9% from 18.3% in the quarter under review.
&#8220;Third quarter organic growth was driven by favorable timing in Essential Dental Solutions of approximately $20 million related to stocking orders in anticipation of U.S. ERP deployment, and higher sales in CAD/CAM, which benefited from the launch of our new scanner, Primescan 2,&#8221; said Simon Campion, President and Chief Executive Officer.
&#8220;Due to ongoing market pressures impacting equipment in the U.S., as well as the evolving landscape with Byte, we are lowering our full year organic sales outlook,&#8221; Campion added.
The company had $296 million of cash and cash equivalents as of September&nbsp;30. Long-term debt as of quarter end totaled $1.795 billion.
Guidance:&nbsp;Dentsply Sirona revised its 2024 outlook due to market pressures impacting U.S. equipment, legislative changes affecting the direct-to-consumer aligner business model, and the voluntary <a href="https://www.benzinga.com//node/41532952">suspension of sales, marketing, and shipments of Byte Aligners and Impression Kits.</a>
The revised sales forecast is $3.79 billion &#8211; $3.83 billion, versus prior guidance of $3.86 billion &#8211; $3.90 billion and consensus of $3.878 billion, with an organic sales decline of 3.5% &#8211; 2.5% year over year.
The company expects 2024 adjusted EPS of $1.82 &#8211; $1.86 versus <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">prior guidance of $1.96 &#8211; $2.02 and consensus of $1.98.</a>
William Blair&nbsp;noted that some negative events have affected the stock since upgrading Dentsply Sirona last year. However, the firm still believes the stock offers an appealing risk-to-reward balance for a leading dental company with broad capabilities and strong potential in a promising market.
&#8220;We think the aforementioned headwinds will likely make shares a &#8220;show me&#8221; story in the near term but expect execution on operational efficiencies and potentially improving macro in the coming quarters can support the stock,&#8221; the analyst writes. William Blair&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/XRAY/analyst-ratings" rel="noreferrer noopener">maintains the Outperform rating</a>.
Leerink Partners&nbsp;has downgraded Dentsply Sirona from Outperform to Market Perform.
Price Action: XRAY shares are trading lower by 25% to $18.02 at last check Thursday.
Image via Pexels/ Karolina Kaboompics
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/41803738" target="_blank" rel="noreferrer noopener">Invesco Launches New ETFs Targeting AI, Cybersecurity, And Defense. Here&#8217;s How Some Of Their Peers Have Performed In The Past Year</a></li>
</ul>

Analyst Color

Guidance

Reiteration

Analyst Ratings

General

Dentsply Sirona Stock Sinks On Dismal 2024 Guidance, Blames Macroeconomic, Competitive Pressures And Weakened Demand

WIIM

Dentsply Sirona shares are trading lower after the company lowered its FY24 guidance and Leerink Partners downgraded the stock from Outperform to Market Perform.

Leerink Partners analyst Michael Cherny downgrades Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) from Outperform to Market Perform.

Downgrades

Leerink Partners Downgrades Dentsply Sirona to Market Perform

Health Care

Dentsply Sirona Expects 2024 Adjusted EPS Of $1.82-$1.86 Versus Prior Guidance Of $1.96-$2.02 And Consensus Of $1.98

The Company is revising its 2024 outlook due to market pressures impacting U.S. equipment, legislative changes affecting the direct-to-consumer aligner business model, and the voluntary suspension of sales, marketing, and shipments of Byte Aligners and Impression Kits. The revised outlook includes expected net sales in the range of $3.79 billion to $3.83 billion, and organic sales are expected to be in the range of (3.5%) to (2.5%) year-over-year. Adjusted EPS is expected to be in the range of $1.82 to $1.86. The outlook does not include potential adjustments or impacts of additional Byte remediation measures or decisions made by the Company.

Dentsply Sirona Expects 2024 Sales Of $3.79B-$3.83B Versus Prior Guidance Of $3.86B-$3.90B And Consensus Of $3.878B

Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) reported quarterly earnings of $0.50 per share which beat the analyst consensus estimate of $0.47 by 6.38 percent. The company reported quarterly sales of $951.00 million which beat the analyst consensus estimate of $939.10 million by 1.27 percent. This is a 0.42 percent increase over sales of $947.00 million the same period last year.

Dentsply Sirona Q3 2024 Adj EPS $0.50 Beats $0.47 Estimate, Sales $951.00M Beat $939.10M Estimate

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Baird raised AAON, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAON#NASDAQ">AAON</a>) price target from $114 to $130. Baird analyst Timothy Wojs upgraded the stock from Neutral to Outperform. AAON shares closed at $111.19 on Friday. See how other analysts view this stock.</li>
<li>BMO Capital increased the price target for Saia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) from $465 to $495. BMO Capital analyst Fadi Chamoun maintained a Market Perform rating. Saia shares closed at $461.65 on Friday. <a href="https://www.benzinga.com/quote/SAIA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley raised the price target for Nutanix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>) from $71 to $72. Morgan Stanley analyst Meta Marshall upgraded the stock from Equal-Weight to Overweight. Nutanix shares closed at $61.59 on Friday. <a href="https://www.benzinga.com/quote/NTNX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity raised Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) price target from $278 to $298. Canaccord Genuity analyst George Gianarikas maintained a Buy rating. Tesla shares settled at $269.19 on Friday. <a href="https://www.benzinga.com/quote/TSLA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham cut DENTSPLY SIRONA Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) price target from $34 to $29. Needham analyst David Saxon maintained a Buy rating. DENTSPLY SIRONA shares closed at $23.31 on Friday. <a href="https://www.benzinga.com/quote/XRAY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Benchmark raised Plexus Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLXS#NASDAQ">PLXS</a>) price target from $150 to $165. Benchmark analyst David Williams maintained a Buy rating. Plexus shares closed at $141.19 on Friday. <a href="https://www.benzinga.com/quote/PLXS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler cut the price target for Wayfair Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) from $67 to $63. Piper Sandler analyst Peter Keith maintained an Overweight rating. Wayfair shares settled at $44.39 on Friday. <a href="https://www.benzinga.com/quote/W/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler raised CME Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>) price target from $240 to $250. Piper Sandler analyst Patrick Moley maintained an Overweight rating. CME Group shares closed at $226.14 on Friday. <a href="https://www.benzinga.com/quote/CME/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital cut the price target for Hexcel Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HXL#NYSE">HXL</a>) from $70 to $68. BMO Capital analyst John McNulty maintained a Market Perform rating. Hexcel shares closed at $62.53 on Friday. <a href="https://www.benzinga.com/quote/HXL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc boosted Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) price target from $86 to $87. Keybanc analyst Bradley Thomas maintained an Overweight rating. Walmart shares closed at $82.51 on Friday. <a href="https://www.benzinga.com/quote/WMT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying TSLA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="519" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/28091724/image-275-1024x519.png" alt="" class="wp-image-617086" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/28091724/image-275-1024x519.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/28091724/image-275-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/28091724/image-275-768x389.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/28091724/image-275.png 1227w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41573022/how-to-earn-500-a-month-from-ford-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Ford Stock Ahead Of Q3 Earnings</a></li>
</ul>

Price Target

Pre-Market Outlook

AAON

NTNX

PLXS

SAIA

TSLA

Tesla To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday

Throughout the last three months, 5 analysts have evaluated Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $32.0, a high estimate of $36.00, and a low estimate of $27.00. Observing a downward trend, the current average is 5.33% lower than the prior average price target of $33.80. 
<img src="https://www.benzinga.com/files/images/story/2024/1730116819_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Dentsply Sirona is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$29.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$27.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$34.00</td>
<td>$36.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Dentsply Sirona. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Dentsply Sirona compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Dentsply Sirona's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/XRAY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Dentsply Sirona analyst ratings.</a>
<h2>Unveiling the Story Behind Dentsply Sirona</h2>
Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (manufactured dental consumables and lab products) and Sirona Dental Systems (manufactured technologically-advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology and equipment through third-party distributors and the remaining portfolio is either sold to labs and offices through the firm's salesforce or directly to consumers (such as Byte clear aligner).
<h3>Dentsply Sirona: Delving into Financials</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Challenges: Dentsply Sirona's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -4.28%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -0.41%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Dentsply Sirona's ROE excels beyond industry benchmarks, reaching -0.13%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Dentsply Sirona's ROA excels beyond industry benchmarks, reaching -0.06%. This signifies efficient management of assets and strong financial health.
Debt Management: Dentsply Sirona's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.72.
<h2>What Are Analyst Ratings?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Latest Analyst Ratings For Dentsply Sirona

Needham analyst David Saxon maintains Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Buy and lowers the price target from $34 to $29.

Needham Maintains Buy on Dentsply Sirona, Lowers Price Target to $29

Dentsply Sirona Plans To Evaluate And Assess Appropriate Next Steps For Byte; Says It May Incur Additional Impairments And Write-offs Regarding This Business, Which May Be Material In Current And Future Periods

For the&nbsp;third quarter&nbsp;2024, the Company expects to report year-over-year net sales growth in Essential Dental Solutions, partially offset by declines in Orthodontic and Implant Solutions and Connected Technology Solutions segments.
Wellspect Healthcare net sales are expected to be approximately flat due to timing with a large US distributor.&nbsp;
The Company expects to record non-cash charges for the impairment of goodwill within the range of&nbsp;$450&nbsp;-&nbsp;$550 million, net of tax, pertaining to two of its reporting units, Orthodontic Aligner Solutions and Implants &amp; Prosthetic Solutions, which together comprise the Orthodontic and Implant Solutions segment.&nbsp;
Several&nbsp;factors contributed to reductions to forecasted revenues, lower operating margins, and expectations for lower future cash flows in the near term, resulting in an impairment during the&nbsp;third quarter&nbsp;for the aforementioned reporting units.

Dentsply Sirona Reports Preliminary Q3 Net Sales Of Approximately $951M (Est $937.91M) And Adjusted EPS Of $0.49 - $0.51 (Est $0.47) 

The Company&#39;s decision was made in consultation with the U.S. Food and Drug Administration (FDA).

Dentsply Sirona Suspends Sales And Marketing Of Its Byte Aligners And Impression Kits While Conducting Review Of Certain Regulatory Requirements Related To These Products

In the latest quarter, 6 analysts provided ratings for Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>), showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $31.67, a high estimate of $36.00, and a low estimate of $27.00. This current average has decreased by 4.03% from the previous average price target of $33.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1728410450_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of Dentsply Sirona by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$27.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$34.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Jeffrey Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$31.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$28.00</td>
<td>$30.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Dentsply Sirona. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Dentsply Sirona compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Dentsply Sirona's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Dentsply Sirona's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/XRAY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Dentsply Sirona analyst ratings.</a>
<h2>All You Need to Know About Dentsply Sirona</h2>
Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (manufactured dental consumables and lab products) and Sirona Dental Systems (manufactured technologically-advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology and equipment through third-party distributors and the remaining portfolio is either sold to labs and offices through the firm's salesforce or directly to consumers (such as Byte clear aligner).
<h3>Dentsply Sirona: A Financial Overview</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Challenges: Dentsply Sirona's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -4.28%. This indicates a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Dentsply Sirona's net margin is impressive, surpassing industry averages. With a net margin of -0.41%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Dentsply Sirona's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.13% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Dentsply Sirona's ROA stands out, surpassing industry averages. With an impressive ROA of -0.06%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Dentsply Sirona's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.72.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Navigating 6 Analyst Ratings For Dentsply Sirona

Evercore ISI Group analyst Elizabeth Anderson maintains Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Outperform and lowers the price target from $29 to $27.

Evercore ISI Group Maintains Outperform on Dentsply Sirona, Lowers Price Target to $27

Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $32.0, a high estimate of $38.00, and a low estimate of $27.00. Experiencing a 5.19% decline, the current average is now lower than the previous average price target of $33.75. 
<img src="https://www.benzinga.com/files/images/story/2024/1726848086_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Dentsply Sirona. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$34.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Jeffrey Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$31.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$28.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$27.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$28.00</td>
<td>$35.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Dentsply Sirona. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Dentsply Sirona compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Dentsply Sirona's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Dentsply Sirona's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/XRAY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Dentsply Sirona analyst ratings.</a>
<h2>Delving into Dentsply Sirona's Background</h2>
Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (manufactured dental consumables and lab products) and Sirona Dental Systems (manufactured technologically-advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology and equipment through third-party distributors and the remaining portfolio is either sold to labs and offices through the firm's salesforce or directly to consumers (such as Byte clear aligner).
<h3>Breaking Down Dentsply Sirona's Financial Performance</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Challenges: Dentsply Sirona's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -4.28%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Dentsply Sirona's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -0.41%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -0.13%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -0.06%, the company showcases effective utilization of assets.
Debt Management: Dentsply Sirona's debt-to-equity ratio is below the industry average at 0.72, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Dentsply Sirona's Future

Barrington Research analyst Michael Petusky maintains Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Outperform and maintains $36 price target.

Barrington Research Maintains Outperform on Dentsply Sirona, Maintains $36 Price Target

Dentsply Sirona shares are trading lower. The company announced the resignation of its CFO and executive vice president and will begin searching for a replacement immediately.

Needham analyst David Saxon has maintained their bullish stance on XRAY stock, giving a Buy rating today. David Saxon has given his Buy rating due ...

DENTSPLY SIRONA Receives Buy Rating Amid Strong Performance and Strategic Adjustments

Analyst Michael Cherny of Leerink Partners maintained a Buy rating on DENTSPLY SIRONA (XRAY – Research Report), reducing the price target to $32.00...

DENTSPLY SIRONA: Navigating Challenges with Stability and Upside Potential Justifies 'Buy' Rating

Envista upgraded to market perform by Leerink, management cited

Dentsply Sirona Non-GAAP EPS of $0.50 beats by $0.02, revenue of $951M beats by $11.11M

DENTSPLY SIRONA ( ($XRAY) ) has shared an announcement. DENTSPLY SIRONA reported a modest increase in third quarter sales, driven by strong perform...

DENTSPLY SIRONA Revises Outlook Amid Goodwill Impairments

As previously reported, Leerink downgraded Dentsply Sirona (XRAY) to Market Perform from Outperform with a price target of $21, down from $32, citi...

Dentsply Sirona downgraded to Market Perform at Leerink on lack of visibility

Leerink downgraded Dentsply Sirona (XRAY) to Market Perform from Outperform. Published first on TheFly – the ultimate source for real-time, market-...

Dentsply Sirona downgraded to Market Perform from Outperform at Leerink

Needham analyst David Saxon maintained a Buy rating on DENTSPLY SIRONA (XRAY – Research Report) today and set a price target of $23.00. David Saxon...

DENTSPLY SIRONA: Buy Rating Amid 2024 Challenges and Strategic Outlook for Recovery

DENTSPLY SIRONA Inc. 2024 Q3 - Results - Earnings Call Presentation

DENTSPLY SIRONA Inc. (XRAY) Q3 2024 Earnings Call Transcript

NVST

Press Releases

Dentsply Sirona Reports Second Quarter 2024 Results and Announces Second Phase of Transformation

Dentsply Sirona Initiates Search for New CFO

Dentsply Sirona to Participate in Upcoming Investor Conferences

Dentsply Sirona presents Primescan® 2 powered by DS Core: The first cloud-native intraoral scanning solution

Legal

Kaskela Law LLC Announces Shareholder Investigation of Dentsply Sirona Inc. (NASDAQ: XRAY) and Encourages Long-Term XRAY Shareholders to Contact the Firm

Comments

Dentsply Sirona

Dentsply Sirona (XRAY) Opciones

Dentsply Sirona (NASDAQ:XRAY) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL